Literature DB >> 19580963

Fenofibrate causes regression of endometriotic implants: a rat model.

Gogsen Onalan1, Hulusi B Zeyneloglu, Nilufer Bayraktar.   

Abstract

Fenofibrate -a peroxisome proliferator-activated receptor-a agonist- is an angiostatic agent that is commonly used in human liver diseases, therefore it may interfere with the angiogenetic process required for endometriosis. In a rat endometriosis model, we demonstrated that peritoneal implant areas and vascular endothelial growth factor levels in the peritoneal flud were significantly decreased in high dose or low dose finofibrate and luprolide acetate treated groups compared to control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19580963     DOI: 10.1016/j.fertnstert.2009.05.065

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model.

Authors:  Fang Liu; Li Wang; Xian-Xia Zhang; Shu-Yun Min; Yi-Xuan Liu; Zhi Zuo; Zhi-Xing Jin; Zhi-Ling Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  Anti-Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms.

Authors:  Weilin Zheng; Lixing Cao; Zheng Xu; Yuanyuan Ma; Xuefang Liang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-01       Impact factor: 2.629

3.  Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models.

Authors:  Zhengyun Chen; Chunyan Wang; Cuicui Lin; Lifeng Zhang; Huimei Zheng; Yong Zhou; Xiaoyong Li; Chen Li; Xinmei Zhang; Xiaohang Yang; Minxin Guan; Yongmei Xi
Journal:  Oxid Med Cell Longev       Date:  2021-09-11       Impact factor: 6.543

Review 4.  Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis.

Authors:  Monica S Chung; Sang Jun Han
Journal:  Front Glob Womens Health       Date:  2022-04-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.